Khalis Mustafayev

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

KhalisMustafayev, Research Scientist at Miami Cancer Institute, shared on X:

“Are BCR::ABL1 TKIs safe for cancer patients with chronic Hepatitis C? Our latest study explores the virologic effect and hepatotoxicity of BCR::ABL1 TKIs.”

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study – ScienceDirect

Authors: Khalis Mustafayev, Eduardo Yepez Guevara, Courtney D. DiNardo, Elias Jabbour, Issa C. Ghayas, Ravin Ratan, Naveen Pemmaraju, Harrys A. Torres

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

cancer Courtney D. DiNardo Eduardo Yepez Guevara Elias Jabbour Harrys A. Torres hepatitis C Issa C. Ghayas Khalis Mustafayev Naveen Pemmaraju OncoDaily Oncology Ravin Ratan